OR WAIT null SECS
The company announced that it would now be offering a portfolio of fresh and cryopreserved human and animal hepatocytes for ADME-Tox testing.
On March 16, 2017 Lonza announced that it now offers a portfolio of fresh and cryopreserved human and animal hepatocytes for absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) testing, for use in cell discovery applications. This expansion of Lonza’s primary cells range is the result of last year’s acquisition of hepatocyte provider, Triangle Research Laboratories (TRL). The inclusion of TRL’s experience allows Lonza to provide high-quality hepatocytes for in-vitro drug metabolism and pharmacokinetic studies and research.
The ADME-Tox products support researchers with a variety of in-vitro applications, including studies into drug metabolism and toxicity, drug-transporter activity, and drug-drug interactions. The new hepatocyte portfolio also features hepatic non-parenchymal cells, such as stellate and Kupffer cells, which can improve the translatability of in-vitro toxicity testing and pharmacokinetics research to clinical trials.
Lonza’s hepatocytes are prequalified for a variety of different applications. The new range also includes supporting ADME-Tox products including specialized hepatocyte media and cell culture systems, helping to optimize hepatocyte culture performance for in-vitro drug screening or for research into drug-induced liver injury and other important liver diseases.